Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer

Inclusion Criteria: * Patient has histologically or cytologically confirmed resectable, borderline resectable, or locally advanced (unresectable) PDAC (based upon Tempero et al 2016) * Age ≥ 18 years. * If a female patient is of child-bearing potential, she must have a negative serum pregnancy test (≥β-hCG) documented within 72 hours of the first administration of study drug * If sexually active, the patient and partner must agree to use contraception considered adequate and appropriate by the Investigator * Patient must have received no prior chemotherapy or radiation therapy for PDAC * Patients must have normal organ and marrow function * Patient has acceptable coagulation status as indicated by an INR ≤ 1.5 x ULN. Patients on anticoagulation can be included at the discretion of the investigator. * Karnofsky Performance Status (KPS) of ≥70%. * Have an elevated CA 19-9 (\>2X ULN) in the context of normal bilirubin Exclusion Criteria: * Patient will be excluded from this study if any of the following criteria apply: Evidence of metastatic disease. No metastatic disease defined as any one or more of the following; Suspicious lymphadenopathy outside of the standard surgical field (i.e. aortocaval nodes, distant abdominal nodes) or Radiographic evidence for metastatic disease in distant organs, peritoneum, or ascites * Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. * Known infection with HIV, hepatitis B, or hepatitis C. * Has underg…